American International Group Inc vs Summit Therapeutics Inc — how do they compare? American International Group Inc trades at $76.02 (market cap $40.42B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: American International Group Inc is far larger — about 3.4× Summit Therapeutics Inc's market cap, and American International Group Inc pays a 2.59% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AIG | SMMT | |
|---|---|---|
Market Cap | $40.42B | $12.06B |
Sector | Financials | Health |
52-Week High | $86.59 | $26.98 |
52-Week Low | $71.89 | $12.55 |
Enterprise Value | $48.06B | $11.39B |
Dividend Yield | 2.59% | — |
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.33, down 1.65% on the day, with a bearish technical signal and neutral oscillators. The company shows strong earnings momentum with three consecutive quarterly beats (Q4 2025: $1.96 vs $1.90 expected, Q1 2026: $2.11 vs $1.89, Q2 2026: $2.00 vs $1.92) and maintains a 11.12% net income margin. Recent news highlights CEO Eric Anderson discussing geopolitical opportunities and strong Q2 results with 10% adjusted EPS growth.
AIG presents a mixed outlook with solid fundamentals and earnings consistency offset by bearish technicals. The 12-month consensus price target of $89.00 suggests 16.6% upside potential, supported by 39% analyst buy ratings. Key risks include competitive pricing pressure in North American property insurance and market volatility. The stock's current valuation at 14.11 P/E appears reasonable given earnings growth trajectory.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →